At any given moment, the other 97% are not in a buying window. They’re not evaluating options, comparing vendors, or thinking about the problem your solution solves. And no amount of outreach, nurture content, or pipeline volume will change that timeline.
What you can control is what happens when those buyers finally do start looking: whether they find you, recognize you immediately, and trust that you’re the right fit before they ever speak to your team.
That’s the real job of marketing in healthcare. Not manufacturing urgency. Not converting the unconvinced. Being so visible, credible, and specific that the 3% who are already ready can’t miss you.
The companies that build the strongest pipelines are not the loudest ones. They are the clearest ones.
Most growth-stage healthcare companies are optimizing for the wrong thing. The GTM motion is built around volume and velocity, with more outreach, more sequences, more content that targets a market that isn’t cold, it’s simply not ready yet.
The result is significant activity with very little signal. Pipeline metrics look busy. But the deals that close are founder-led, referral-driven, or come from a relationship that already existed. The commercialization engine is generating noise, not buyers.
As we outlined in 16 Lessons Healthcare Companies Learn Too Late: positioning breaks before revenue does. By the time a company starts losing deals it expected to win, the wrong pipeline has already been built and is attracting the wrong buyers, generating the wrong case studies, and reinforcing the wrong proof points.
The 3% who are actively evaluating are not passive. They’re doing research, having internal conversations, scanning their networks for signals. They will find someone. The question is whether they’ll find you and whether your message will land with enough clarity that they recognize you as the right fit without friction.
That’s a recognition problem. Not a reach problem. And it requires a different kind of solution.
When we work with healthcare companies on message strategy and market positioning, we evaluate readiness across three dimensions. Each maps to a distinct failure mode we see consistently in this market.
Visibility is not awareness. The goal is not for everyone to know your name, it’s for the right people to encounter your signal at the exact moment a problem becomes urgent. That means being present in the channels buyers actually use: peer networks, analyst briefings, industry publications, and the search queries that surface when a health system VP needs a solution approved by Q3.
The question is not how many people see you. It is whether the right people encounter you at the right moment.
Healthcare buyers are not extending the benefit of the doubt. They’ve been burned by overpromised pilots and compelling decks that fell apart in implementation. When they encounter your company, they are scanning immediately for proof.
Credibility comes from specificity of outcomes, not breadth of claims. As we noted in Lesson 6: proof wins over narrative. A case study documenting exactly how a specialty pharmacy platform reduced readmissions by 18% in a Medicaid population is worth more than a hundred slides about “transforming healthcare.” The evidence has to exist, be documented, and be accessible before the first call happens.
A message built to appeal to everyone appeals to no one. When a health system CFO reads your positioning, it should feel written for them. When a PE operating partner evaluates your capabilities, they should immediately see the overlap with the portfolio company they’re trying to scale.
Specificity feels like narrowing. It isn’t. The buyer whose problem you name precisely is far more likely to move quickly. The buyer whose problem you don’t name wasn’t going to convert at the speed or margin you need anyway. Specificity is what turns the 3% into fast closes instead of pilot purgatory.
For a mid-market health tech CEO under investor pressure: your message needs to signal enterprise value, not just clinical differentiation. Buyers are evaluating whether your solution is a scalable infrastructure play or a bespoke engagement. If your positioning doesn’t answer that immediately, you’re pulling in the wrong pipeline.
For a CMO or Head of Growth defending marketing spend: specificity is how you shorten the sales cycle and reduce customer acquisition cost. When marketing speaks the exact language of your target buyer, handoffs tighten, conversion improves, and the attribution story becomes defensible at the board level. Vague positioning is not a brand problem. It’s a revenue problem.
For a PE operating partner evaluating portfolio GTM: message clarity is a valuation signal. If a company can’t articulate who they serve and why they win in plain language, that gap will surface in diligence, compress multiples, and create friction in the sale. Lesson 10 applies here directly: speed without clarity creates rework. The time to fix positioning is not during the mergers and acquisitions process.
The job of marketing is not to convince the unconvinced. It’s to be impossible to miss for the buyers who are already ready.
The companies that consistently attract the right buyers didn’t stumble into clarity. They built commercial infrastructure, not just campaigns. They stayed specific under pressure to go broad. They documented proof before they needed it in a deal room.
As Lesson 14 puts it: enterprise value is engineered, not hoped for. Message clarity is one of those deliberate choices. It belongs at the leadership level because it has direct implications for pipeline quality, sales cycle length, and what a buyer sees when they evaluate your business.
The companies that win in this market aren’t always the ones with the best solution. They’re the ones who made it impossible for the right buyers to overlook them.
That’s the work. And it starts with the message.
Volume and conversion are different problems. A pipeline built on broad messaging attracts buyers who are curious but not ready. What closes deals in healthcare is the moment a qualified buyer encounters your message and immediately recognizes you understand their specific problem. If pipeline is busy but conversion is slow, the issue usually isn't lead volume — it's lead fit.
The 97% will enter a buying window eventually. The question is whether you'll be the obvious choice when they do. That doesn't require constant outreach to people who aren't ready — it requires building visibility and proof over time so that when the window opens, you're already in their field of view. Chasing the 97% actively is expensive and usually produces the wrong pipeline.
Specificity doesn't mean serving fewer buyers. It means speaking to each buyer as though you understand their world distinctly. A health system CFO and a PE operating partner may both benefit from your solution, but the problem they're solving and the proof they need to act are very different. The goal is a clear core narrative with buyer-specific articulations underneath it — that's not narrowing, it's architecture.
A few reliable signals: your team describes the business differently depending on who's in the room; your website reflects a company you were two or three years ago; or deals stall at the point where buyers need to explain your value internally. Positioning is a leading indicator — the revenue impact shows up later, which means by the time it's obvious, the wrong pipeline has already been built.
A brand refresh is downstream — new look, updated language, revised website. Positioning is the strategic foundation underneath it: who you serve, what problem you solve better than anyone else, and why a sophisticated buyer should choose you. Companies that invest in brand before resolving positioning end up with a polished version of an unclear message. Positioning comes first.
It matters at every stage, but the cost of getting it wrong scales as the business grows. Early on, founders compensate through relationships and persistence. At growth stage, that stops being a workaround and becomes a liability — the GTM motion needs to be repeatable without the founder at the center. For companies approaching an exit, message clarity is a valuation issue. Buyers aren't just evaluating revenue; they're evaluating whether the growth story is transferable.
